Myasthenia gravis: Five new things

Neurology: Clinical Practice

Volumn 3, Issue 2, 2013, Pages 126-133

  Statland, Jeffrey M ^a   Ciafaloni, Emma ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; MUSK ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY TITER; BREATHING MUSCLE; CHILL; DISEASE SEVERITY; DRUG ERUPTION; DYSPNEA; FIRST TRIMESTER PREGNANCY; FLU LIKE SYNDROME; FLUSHING; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTENSIVE CARE UNIT; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; PRURITUS; PUERPERIUM; REVIEW; RIGOR; SIDE EFFECT; SMALL FOR DATE INFANT; STERNOTOMY; THORACOTOMY; THYMECTOMY; THYMOMA; TREATMENT CONTRAINDICATION; WEAKNESS;

EID: 84880107113     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e31828d9fec     Document Type: Review

References (22)

1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010;10:46.
2. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76:2017-2023.
3. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and highdose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-796.
4. Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 2012;45:909-917.
5. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-632.
6. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78: 1009-1015.
7. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300.
8. Kaminski HJ, Cutter G, Ruff R. Practice parameters and focusing research: plasma exchange for myasthenia gravis. Muscle Nerve 2011;43:625-626.
9. Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011; 13:85-94.
10. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010;41:370-374.
11. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
12. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44:36-40.
13. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
14. Zahid I, Sharif S, Routledge T, Scarci M. Video-assisted thoracoscopic surgery or transsternal thymectomy in the treatment of myasthenia gravis? Interact Cardiovasc Thorac Surg 2011;12:40-46.
15. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:659-663.
16. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78:189-193.
17. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4:259-266.
18. Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;121:129-138.
19. Wen JC, Liu TC, Chen YH, Chen SF, Lin HC, Tsai WC. No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population-based study. Eur J Neurol 2009;16:889-894.
20. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-451.
21. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- And MuSK-antibodynegative myasthenia gravis. J Neurol 2012;259:427-435.
22. Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012;69:994-1001.